Elizabeth Burton, Chief Strategist at Fortress Investment Group, assesses the broader investment landscape and where she sees opportunity as investors balance growth against emerging risks.<br><br>Health care takes center stage as Courtney Breen of Bernstein breaks down developments involving Moderna and Merck and what they mean for biotech and pharmaceutical investors as both stocks soar following promising results in a late-stage trial. Moderna jumped nearly 200%. Lo Toney of Plexo Capital tackles a key question in the AI race: is OpenAI losing momentum? Our Eunice Yoon reports on a Chinese humanoid robotics company going public and what the deal reveals about China’s ambitions in robotics and AI. Finally, Kate McShane of Goldman Sachs analyzes the latest retail movers, reacts to Target and previews Walmart earnings as investors search for fresh signals on the health of the consumer.<br><br>Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Closing Bell Overtime: Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar 8/19/26

Closing Bell

The Bell is bringing an end to the trading day at the NYSE Citro Tech, ringing the bell, not the Nasdaq. USA Fencing. Welcome to Closing Bell Overtime, we're live from Studio B at the Nasdaq Market Site. I'm Melissa Lee along with Mike Santoli. Stocks with small gains as the Treasury Department doubles down on its debt repurchase program. The Dow up about 100 points, the S&P 500 back above 7700, the Nasdaq just a tenth of a percent higher. Bond yields pulling back on that news, especially the 30-year which had been near 2007 highs, and that also having an impact on crypto.

Bitcoin having its best day in nearly six months as the dollar declines as well. And a huge success in treating cancer, sending Moderna stock up 180 percent. Much more on that story coming up, but obviously the big news is the effective cap that's been put on, at least for today, on the longer end of the Treasury curve. And that was good enough to send a broadening of the market once again. RSP, new high. New high. I mean, you know, this has been the pattern. So you have semis down. Again, semis are caught up in their own drama, right? They were oversold.

They rallied. Now they hit resistance. And then the rest of the market goes up. Apple up 2%, right? Why? Because semis are down. I mean, really, that's kind of a game we're playing. On the yield side, I mean, it's worth mentioning, I guess, at the outset, this is something the Treasury does. It buys back these kind of less liquid, longer-term securities, kind of cleaning things up and taking advantage of lower Treasury prices.

Closing Bell Overtime: Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar 8/19/26

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Closing Bell Overtime: Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar 8/19/26

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.